Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00120328
Status:
TERMINATED
Last Update Posted:
2007-10-05
First Post:
2005-06-30
Brief Title:
To Determine the Effects of Avosentan on Doubling of Serum Creatinine End Stage Renal Disease and Death in Diabetic Nephropathy
Sponsor:
Speedel Pharma Ltd
Organization:
Speedel Pharma Ltd
Organization Data
Organization:
Speedel Pharma Ltd
Class:
INDUSTRY
Study ID:
SPP301CRD15
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Speedel Pharma Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None